A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, will support research to further explore how chronic stress impacts cancer development.
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers.
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), UC Davis Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the U.S. Centers for Disease Control and Prevention (CDC)
Researchers at Seattle’s Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell carcinoma, a rare, aggressive skin cancer.
Findings uncover an ancient mechanism that makes cancer cells invasive, explains melanoma’s resistance to therapy and opens the door to development of novel cancer therapies
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), Yale Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).
A new therapy in development for the treatment of midgut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, shows improved progression-free survival and response rates for patients with advanced disease. Results of the international phase 3 clinical trial of lutetium-177 (177Lu)-Dotatate compared to high-dose octreotide LAR were published in the Jan. 12 issue of the New England Journal of Medicine.
TAMPA, Fla. – Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system.
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by The University of Texas MD Anderson Cancer Center, Deerfield Management and two leading autophagy experts.
As the nation's 69 National Cancer Institute-designated cancer centers come together in support of recently updated HPV vaccination recommendations, a Rutgers Cancer Institute of New Jersey gynecologic oncologist shares insight on how this vaccine can help prevent cervical cancer.
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement endorsing the recently revised vaccination recommendations from the Centers for Disease Control and Prevention (CDC).
Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD, Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner. The findings have been published online ahead of print in the journal Oncotarget.
Twenty-seven percent of 50 heavily pretreated patients with stage IV breast cancer saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.
BUFFALO, N.Y. — Predisposition to cancer and cancer progression can result from gene mutations that cause elevated rates of genetic damage. Similarly, carcinogens, including some that are used in chemotherapy during cancer treatment, act by damaging the DNA. A new study from Roswell Park Cancer Institute offers insights into the mechanisms that can lead to genetic mutations and proposes opportunities for developing prognostic tests for specific blood disorders and blood cancers based on these striking findings. The study has been published online ahead of print in the journal PLOS Genetics.
NCCN has published NCCN Guidelines for Patients®: Brain Cancer – Gliomas, available today on NCCN.org/patients and NCCN Patient Guides for Cancer mobile app
Sarah Adams, MD, recently opened a clinical trial to test a new approach to defeat ovarian cancer. The clinical trial treats women whose ovarian cancer results from mutated BRCA genes. It uses one drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.
Karla Kerlikowske, MD, and team recently published a paper in the Journal of the National Cancer Institute that examined the role of common risk factors in the development of ER-positive and ER-negative breast cancers. The study sheds new light on how a woman’s age, weight, and menopausal status affect her risk for breast cancer. Dr. Kerlikowske discusses the findings below.
The Connecticut Region of the National Organization of Italian American Women (NOIAW) will honor three of Connecticut’s most prominent and pioneering women at its eighth annual Epiphany Celebration brunch and silent auction event, on Sunday, January 15, 2017, at the New Haven Lawn Club in New Haven, CT.
In a Yale-led study, Qin Yan and his co-authors focused on a family of enzymes — known as KDM5 — that have been shown in previous studies to be involved in cancer cell growth and spreading.
The regular use of aspirin lowers the risk for pancreatic cancer by almost 50 percent, a new study in China led by the Yale School of Public Health finds.
A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.
TAMPA, Fla. – Lymphoma is the most common blood cancer. The disease occurs when immune cells called lymphocytes multiply uncontrollably. Cancerous lymphocytes can travel throughout the body and form lymph node tumors. The body has two types of lymphocytes that can develop into lymphoma – B cells and T cells. B-cell lymphomas account for 85 percent of all non-Hodgkin lymphomas and 30 percent of those patients are diagnosed with diffuse large B-cell lymphoma.
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) product.
Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease.
For more than a decade, there has been a focus on involving primary care providers in the follow-up care of cancer survivors. A new study by Rutgers University and Harvard Medical School finds that despite a number of proposed care models, there is limited information on the role that primary care providers play in this care.
One of the main reasons cancer remains difficult to treat is that cancer cells have developed a multitude of mechanisms that allow them to evade destruction by the immune system. One of these escape mechanisms involves a type of immune cell called myeloid-derived suppressor cells (MDSCs). A recent study led by Sharon Evans, PhD, Professor of Oncology and Immunology at Roswell Park Cancer Institute, provides new insight into how MDSCs enable tumor cells to circumvent immune attack and offer the potential for improving cancer immunotherapy. The research has been published today in the journal eLife.
Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers’ efforts to advance bold ideas toward creating or partnering with a commercial entity.
Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise. After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues. However, new clinical trial research shows reducing radiation for some patients with HPV-associated oropharyngeal squamous cell carcinomas can maintain high cure rates while sparing some of these late toxicities.
A consortium directed by UCLA’s Dr. Kalyanam Shivkumar has received a three-year, $8.6 million grant from the National Institutes of Health to map the heart’s nervous system. The group’s goal: To conduct research that leads to new ways to treat cardiovascular disease by targeting nerves in the heart’s nervous system.
Scientists at Dana-Farber Cancer Institute say they have discovered a potential explanation for why brain and heart tissues in very young children are more sensitive to collateral damage from cancer treatment than older individuals.
Researchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.
A collaborative team of researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Program, led by Alexander Anderson, Ph.D., and Oxford University’s Department of Computer Science are using mathematical models to explain how bacteria and cancer cells exploit an evolutionary process known as bet-hedging to resist medical intervention.
The Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has earned recognition by the Center for International Blood and Marrow Transplant Research for outperforming its expected one-year survival rates for allogeneic transplant patients – those who receive donated adult blood-forming stem cells.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
It is with great pleasure that the Ludwig Institute for Cancer Research announces the appointment of Chi Van Dang as its Scientific Director.
Regular use of aspirin by people living in Shanghai, China, was associated with decreased risk for developing pancreatic cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Moffitt Cancer Center researchers have their study published today in The Lancet Oncology describing a novel genomics model that allows a personalized approach to radiation therapy.
A University of Colorado Cancer Center paper published today in the journal Nature Nanotechnology details how the immune system recognizes nanoparticles, potentially paving the way to counteract or avoid this detection.
Memorial Sloan Kettering Cancer Center and Hackensack Meridian Health announced the Memorial Sloan Kettering–Hackensack Meridian Health partnership, a joint venture that will combine both organizations’ unparalleled expertise in all areas of cancer care and research to accelerate new discoveries and improve the lives of patients they jointly serve.
EMMC Cancer Care, located at the Lafayette Family Cancer Center (Brewer, Maine), is the newest member of the Dana-Farber Cancer Care Collaborative. Participation in the Collaborative reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices.
The Association of American Cancer Institutes (AACI) thanks President Barack Obama for signing the 21st Century Cures Act into law today. The legislation includes a NIH Innovation Account, which provides nearly $4.8 billion in funding for the National Institutes of Health (NIH) over the next ten years.
Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy.
New recommendations from breast cancer experts on sentinel lymph node biopsy reinforce the most recent “less-is-more” guidelines for early-stage disease. But a Fred Hutch researcher who helped create the guidelines said many surgeons still perform full lymph node dissection routinely.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right